Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872900 | 0.85 | TACR1 (0.52) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL21596609 | 0.79 | TSHR (0.54) | IDO1 | |
| SCHEMBL8621299 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL7496743 | 0.74 | IDO1 (0.52) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL13307223 | 0.74 | TACR1 (0.58) | TACR1 | |
| SCHEMBL8963934 | 0.73 | TACR1 (0.59) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL3752087 | 0.73 | MAOA (0.50) | — | |
| SCHEMBL1873597 | 0.72 | PLOD2 (0.46) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL8880647 | 0.72 | TACR1 (0.48) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL27591269 | 0.72 | MAOA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179926-B2 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2006014942-A1 | ARYLOXYALKYLAMINE NK-1/SSRI INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | TPH1, SLC6A4, HTR1A | TACR1 26/4885CACNA1F 704/4885CACNA1D 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.